- Home
- LYRA vs GOVX Comparison
LYRA vs GOVX Comparison
Compare LYRA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- GOVX
- Stock Information
- Founded
- LYRA 2005
- GOVX 2001
- Country
- LYRA United States
- GOVX United States
- Employees
- LYRA N/A
- GOVX N/A
- Industry
- LYRA Medical/Dental Instruments
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- GOVX Health Care
- Exchange
- LYRA Nasdaq
- GOVX Nasdaq
- Market Cap
- LYRA 15.0M
- GOVX 15.5M
- IPO Year
- LYRA 2020
- GOVX N/A
- Fundamental
- Price
- LYRA $9.40
- GOVX $0.95
- Analyst Decision
- LYRA Buy
- GOVX Strong Buy
- Analyst Count
- LYRA 2
- GOVX 5
- Target Price
- LYRA $16.00
- GOVX $12.40
- AVG Volume (30 Days)
- LYRA 1.9M
- GOVX 1.5M
- Earning Date
- LYRA 08-13-2025
- GOVX 08-05-2025
- Dividend Yield
- LYRA N/A
- GOVX N/A
- EPS Growth
- LYRA N/A
- GOVX N/A
- EPS
- LYRA N/A
- GOVX N/A
- Revenue
- LYRA $1,185,000.00
- GOVX $5,591,576.00
- Revenue This Year
- LYRA N/A
- GOVX N/A
- Revenue Next Year
- LYRA $1,286.17
- GOVX N/A
- P/E Ratio
- LYRA N/A
- GOVX N/A
- Revenue Growth
- LYRA N/A
- GOVX N/A
- 52 Week Low
- LYRA $3.81
- GOVX $0.73
- 52 Week High
- LYRA $37.50
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- LYRA 45.31
- GOVX 46.22
- Support Level
- LYRA $10.15
- GOVX $0.85
- Resistance Level
- LYRA $14.88
- GOVX $1.39
- Average True Range (ATR)
- LYRA 2.03
- GOVX 0.15
- MACD
- LYRA -0.67
- GOVX -0.02
- Stochastic Oscillator
- LYRA 0.42
- GOVX 18.52
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.